In a recent study, biomarker-guided preemptive AAT therapy was evaluated in high-risk patients on days +7 and +14 post-HSCT; nonetheless, the study found no change in incidences of steroid-refractory GVHD [45]. Here, SERPINA1 is linked to graft versus host disease.